Regenerative medicine techniques in cardiovascular disease: Where is the horizon?

Regenerative Medicine

Volumn 8, Issue 3, 2013, Pages 351-360

  Packer, Claire ^a   Boddice, Beth ^a   Simpson, Sue ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

cardiovascular disease; factor based therapy; regenerative medicine; stem cell therapy

Indexed keywords

ALFERMINOGENE TADENOVEC; CARDIOVASCULAR AGENT; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; GROWTH FACTOR; REVASCOR; THYMOSIN BETA4; UNCLASSIFIED DRUG;

BONE MARROW CELL; CARDIOVASCULAR DISEASE; CELL THERAPY; CLINICAL PRACTICE; HEALTH CARE SYSTEM; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; TISSUE ENGINEERING; UNITED KINGDOM;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; REGENERATIVE MEDICINE;

EID: 84876947844     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.13.21     Document Type: Review

References (44)

1. Murata M, Tohyama, Fukada K. Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery. Pharmacol. Ther. 126, 109-118 (2010).
2. Alexander JM, Bruneau BG. Lessons for cardiac regeneration and repair through development. Trends Mol. Med. 16, 426-434 (2010).
3. Department for Business Innovation and Life Skills. Taking Stock of Regenerative Medicine in the United Kingdom. Department for Business Innovation and Life Skills, Sheffield, UK (2011). 4. Medical Research Council. A Strategy for UK Regenerative Medicine. Medical Research Council, London, UK (2012).
4. Moran N, Sheridan C, Winter P. Regenerate the Future. Science Business Publishing Ltd., Middlesex, UK (2012).
5. Future Medicine. World stem cell report. Global update: USA. Regen. Med. 7(Suppl. 6), 126-129 (2012).
6. Future Medicine. World stem cell report. Global update: Canada. Regen. Med. 7(Suppl. 6), 132-135 (2012).
7. Future Medicine. World stem cell report. Global update: UK. Regen. Med. 7(Suppl. 6), 136-138 (2012).
8. Future Medicine. World stem cell report. Global update: Sweden. Regen. Med. 7(Suppl. 6), 140-142 (2012).
9. Future Medicine. World stem cell report. Global update: Brazil. Regen. Med. 7(Suppl. 6), 144-147 (2012).
10. Ptaszek LM, Mansour M, Ruskin JN, Chien KR. Towards regenerative therapy for cardiac disease. Lancet 379, 933-942 (2012).
11. Vassalli G, Moccetti T. Cardiac repair with allogenic mesenchymal stem cells after myocardial infarction. Swiss Med. Wkly 141, w13209 (2011).
12. Kinkaid HY, Huang XP, Li RK, Weisel RD. What's new in cardiac cell therapy? Allogeneic bone marrow stromal cells as 'universal donor cells'. J. Card. Surg. 25(3), 359-366 (2010).
13. Hare JM, Fishman JE, Gerstenblith G et al. Comparison of allogeneic vs autologous bone-marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy. The POSEIDON randomized trial. JAMA 308(22), 2369-2379 (2012).
14. Clifford DM, Fisher SA, Brunskill SJ et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst. Rev. 2, CD006536 (2012).
15. Losordo DW, Henry TD, Davidson C et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Am. Heart J. 109, 428-436 (2011).
16. Henry TD, Grines CL, Watkins MW et al. Effects of Ad5FGF-4 in patients with angina. J. Am. Coll. Cardiol. 50, 1038-1046 (2007).
17. Reyes G, Allen KB, Alvarez P et al. Mid term results after bone marrow laser revascularization for treating refractory angina. BMC Cardiovasc. Disord. 10, 1-6 (2010).
18. NICE. Transmyocardial Laser Revascularization for Refractory Angina Pectoris. NICE, London, UK (2009).
19. Briones E, Lacalle JR, Marin I. Transmyocardial laser revascularisation versus medical therapy for refractory angina. Cochrane Database Syst. Rev. 21(1), CD003712 (2009).
20. Schächinger V, Erbs S, Elsässer A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355, 1210-1221 (2006).
21. Assmus B, Rolf A, Erbs S et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ. Heart Fail. 3, 89-96 (2010).
22. Dohmann HFR, Silva SA, Sousa ALS et al. Multicenter double blind trial of autologous bone marrow mononuclear cell transplantation through intracoronary injection post acute myocardium infarction - MiHeart/AMI study. Trials 9, 41 (2008).
23. Stamm C, Kleine HD, Choi YH et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J. Thorac. Cardiovasc. Surg. 133, 717-725 (2007).
24. Klein HM, Assmann A, Lichtenberg A, Heke M. Intraoperative CD133+ cell transplantation during coronary artery bypass grafting in ischemic cardiomyopathy. Multimed. Man. Cardiothorac. Surg. doi:10.1510/mmcts.003947 (2009) (Epub ahead of print).
25. Mansour S, Roy DC, Bouchard V et al. Oneyear safety analysis of the COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction. Bone Marrow Res. 2011, 385124 (2011).
26. Ahmadi H, Baharvand H, Ashtiani SK et al. Safety analysis and improved cardiac function following local autologous transplantation of CD133+ enriched bone marrow cells after myocardial infarction. Curr. Neurovasc. Res. 4(3), 153-160 (2007).
27. Ahmadi H, Moshkani Farahani M, Kouhkan A et al. Five-Year follow-up of the local autologous transplantation of CD133+ enriched bone marrow cells in patients with myocardial infarction. Arch. Iran. Med. 15(1), 32-35 (2012).
28. Donndorf P, Kaminski A, Tiedemann G, Kundt G, Steinhoff G. Validating intramyocardial bone marrow stem cell therapy in combination with coronary artery bypass grafting, the PERFECT Phase III randomized multicenter trial: study protocol for a randomized controlled trial. Trials 13, 99 (2012).
29. EMA. Advanced therapy medicinal products and the Committee for Advanced Therapies. EMA, London, UK (2013).
30. dos Santos RR, Rassi S, Feitosa G et al. Cell therapy in chagas cardiomyopathy (Chagas Arm of the Miheart Study): a multicenter randomized trial. Circulation. 125(20), 2454-2461 (2012).
31. univerCELLmarket. www.univercellmarket.com (Accessed 19 April 2012)
32. ClinicalTrials.gov. Efficacy and safety of targeted intramyocardial delivery of auto CD34+ stem cells for improving exercise capacity in subjects with refractory angina (RENEW). www.clinicaltrials.gov/ct/show/ NCT01508910 (Accessed 14 February 2013)
33. ClinicalTrials.gov. Efficacy and safety of Ad5FGF-4 for myocardial ischemia in patients with stable angina due to coronary artery disease (ASPIRE). www.clinicaltrials.gov/ct2/show/NCT015506 14?term=ASPIRE&fund=2&rank=5 (Accessed 14 February 2013)
34. ClinicalTrials.gov. Safety study of transmyocardial revascularization (TMR) with bone marrow aspirate (BMAC) for angina reduction (PHOENIX). www.clinicaltrials.gov/ct2/show/NCT012852 97?term=nct01285297&rank=1 (Accessed 14 February 2013)
35. ClinicalTrials.gov. BAMI. The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all cause mortality in acute myocardial infarction. www.clinicaltrials.gov/ct2/show/NCT015691 78?term=NCT01569178&rank=1 (Accessed 14 February 2013)
36. ClinicalTrials.gov. ESTIMATION study for endocardial mesenchymal stem cells implantation in patients after acute myocardial infarction. www.clinicaltrials.gov/ct2/show/NCT01394 432?term=Estimation&rank=2 (Accessed 14 February 2013)
37. ClinicalTrials.gov. Cell therapy in myocardial infarction (EMRTCC). www.clinicaltrials.gov/ct2/show/NCT00350 766?term=NCT00350766&rank=1 (Accessed 14 February 2013)
38. ClinicalTrials.gov. Intramyocardial transplantation of bone marrow stem cells in addition to coronary artery bypass graft (CABG) surgery (PERFECT). www.clinicaltrials.gov/ct2/show/NCT00950 274?term=NCT00950274&rank=1 (Accessed 14 February 2013)
39. ClinicalTrials.gov. Safety and efficacy of autologous cardiopoietic cells for treatment of ischemic heart failure (CHART1). www.clinicaltrials.gov/ct2/ show/NCT017687 02?term=NCT01768702&rank=1 (Accessed 14 February 2013)
40. Cardio3 BioSciences. www.c3bs.com/en/products-pipeline/clinical. html (Accessed 14 February 2013)
41. ClinicalTrials.gov. Endocardial stem cells approach efficacy (ESCAPE). www.clinicaltrials.gov/ct2/show/ NCT00841958?term=ESCAPE&rank=9 (Accessed 14 February 2013)
42. ClinicalTrials.gov. Cell therapy in chronic ischemic heart disease. www.clinicaltrials.gov/ct2/show/NCT00362 388?term=NCT00362388&rank=1 (Accessed 14 February 2013)
43. Regulation (EC) no 1394/2007 of the European parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. http://eur-lex.europa.eu/ LexUriServ/ LexUriServ.do?uri=OJ:L:2007:324:0121:013 7:en:PDF
44. ClinicalTrials.gov. Cell therapy in dilated cardiomyopathy. www.clinicaltrials.gov/ct2/show/NCT00333 827?term=NCT00333827&rank=1 (Accessed 14 February 2013)